PFIZER VACCINE PARA SA EDAD 12-15, APRUBADO NA NG FDA

Ni Raiza F. Cabugwang
Photo courtesy of pna.gov.ph; Anadolu
Share on facebook
Facebook
Share on twitter
Twitter
Share on email
Email

Inanunsyo ng Department of Health noong Martes, Hunyo 8, na inaprubahan na ng Food and Drug Administration ang bagong emergency use authorization (EUA) ng Pfizer-BioNTech Coronavirus disease 2019 o COVID-19 vaccine, kung saan kasama na sa maaaring turukan ng nasabing bakuna ang mga kabataang edad 12 hanggang 15.

Ayon kay Health Secretary Francisco Duque III maaaring mabakunahan ng Pfizer vaccine ang mga kabataang nasa naturang age group, mayroon man o wala silang comorbidity. Ang comorbidity ay tumutukoy sa pagkakaroon ng isang indibidwal ng dalawa o higit pang sakit.

Gayunpaman, sinabi ng Kalihim na dahil sa kakulangan ng suplay ng bakuna, iyong mga may comorbidity pa lamang ang kasama sa A3 na kategorya, na kasalukuyang binibigyang prayoridad sa pagbabakuna.

Sinang-ayunan ni Health Undersecretary Maria Rosario Vergeire ang pahayag ni Duque. 

“While we welcome more vaccines that are approved for children and adolescents, due to limited vaccine supply, our vaccination strategy remains the same — prioritize the vulnerable and adhere to our prioritization framework. The general consensus of our vaccine experts is to revisit pediatric and adolescent vaccination once our vaccine supply has stabilized. The Vaccine Cluster through Secretary Charlie [Galvez] is doing all they can to secure the doses necessary to vaccinate all eligible populations for free,” saad ng opisyal.

Nauna nang binigyan ng EUA ang Pfizer noong Enero ng taong ito, ngunit para lamang iyon sa mga indibidwal edad 16 taong gulang pataas. 

Naghain naman ng aplikasyon ang Pfizer sa FDA ng Pilipinas noong Mayo 20 upang mabago ang EUA nito matapos aprubahan ng FDA ng Estados Unidos ang pamamahagi ng naturang bakuna sa mga kabataan na nasa 12 hanggang 15 taong gulang.

CONTACT US

Anchored on its mantra, “Sentro ng Katotohanan, Tapat sa Mamamayan”, Balita Central Digital complements and supports the Balita Central newspaper published bi-monthly to combat fake news and to provide the public with easy-to-digest news bits that are sourced solely from the Presidency and government agencies. 

Balita Central is under the supervision of the Bureau of Communications Services (BCS), one of the attached agencies of the Presidential Communications Operations Office (PCOO).

Launched on February 28, 2019 at the Manila Light Rail Transit System Line 2 (LRT-2) Cubao Station, Quezon City, it also aims to raise awareness among local communities about the policies, programs, and accomplishments of the Presidency. 

Through this platform, Balita Central Digital aims to reach further the online community to deliver more accurate information and communication services in order to educate the citizenry regarding national issues which would enlighten them to be engaged and be empowered in contributing to building a better nation.

Balita Central is situated at the BCS Headquarters located beside the Philippine Cancer Society along San Rafael, San Miguel, Malacañang Complex, Manila City. Its official website address is balitacentral.ph.

For inquiries and feedback, Balita Central may be contacted at editorialdesk.bcs@gmail.com.